Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07101588 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial

Name: Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial — clinical trial record (NCT07101588)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 4

SponsorChinese PLA General Hospital

Started2025-01-01

View on ClinicalTrials.gov ↗

Amendment history

2026-03-18

Study Status v1

Re-verified, no change to tracked fields

2025-07-28

Original filing

Chinese PLA General Hospital

193 trials monitored

See 4 trials at risk

This study aims to determine whether the recurrence rate of high-risk acute myeloid leukemia CR1 patients who received allogeneic hematopoietic stem cell transplantation with the Ruxolitinib, Decitabine combined with Bu/Cy or BuF intensive pretreatment regimen is reduced compared with the traditional Bu/Cy or BuFpretreatment regimen.

Trial Details

NCT Number	NCT07101588
Lead Sponsor	Chinese PLA General Hospital Collaborators: The First Affiliated Hospital of Zhengzhou University, Peking University People's Hospital
Conditions	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Enrollment	200 participants
Start Date	2025-01-01
Primary Completion	2028-01-01 (estimated)
Study Completion	2028-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-03-20